21 June 2024
Incanthera
plc
("Incanthera" the
"Company")
Admission
of Subscription Shares
Settlement of Subscription Funds
Incanthera plc (AQSE:
INC), the
specialist oncology company focused on innovative technologies in
oncology and dermatology announces the admission to trading at 8am
today of the new ordinary share subject to the recent subscription
and the receipt of the subscription funds.
On 3 June 2024, the Company
announced a placing by way of an institutional-led conditional
subscription for £2.6 million.
Completion of the subscription for
17,403,681 new ordinary shares ("Subscription Shares"),
representing 14.9 per cent. of the Company's enlarged issued share
capital, was conditional on shareholders approving the grant of
sufficient new share authorities at a general
meeting.
Following all resolutions being duly
passed at a general meeting held on 20 June 2024,
the Company is pleased
to confirm the admission of the
Subscription Shares to trading in the Apex segment of the
AQSE Growth Market at 8am
today.
Following admission of the
Subscription Shares, the Company's issued share capital
comprises 116,680,228 ordinary shares of 2 pence each.
The company is also pleased to
confirm that settlement of subscription funds has occurred today in
line with admission to trading.
Commenting on the Admission of
Subscription Shares and settlement of funds, Chairman, Tim McCarthy
said:
"Today marks a significant evolution
of our shareholder register, as we welcome the admission of the new
shares to trading.
Our growth story and the potential
for global commercial opportunities has attracted support from
respected City institutional investors, both existing shareholders
and new investors into our company, raising £2.6 million. These
funds are being immediately deployed into the scale up of inventory
in preparation for the launch and roll out of Incanthera's Skin
+CELL range, driving growth, revenues and profitability, to the
benefit of all shareholders.
I welcome our new institutional
investors and thank them and our existing shareholders for their
support and confidence in our company at what is a uniquely
exciting stage for our company, as we prepare for launch in
September."
For further information please
contact:
Notes to Editors
About Incanthera plc
Incanthera is a specialist company
focused on innovative technologies in dermatology and
oncology. It seeks to identify and develop innovative solutions to
current clinical, commercially relevant unmet needs, utilising new
technology from leading specialists and academic institutions as
well as its in-house development team.
The Company originated from
the Institute of Cancer Therapeutics ("ICT") at
the University of Bradford. Incanthera's strategy
is to develop each candidate in its portfolio from initial
acquisition or discovery to securing its future through
commercially valuable partnerships at the earliest opportunity in
its development pathway.
For more information on the Company
please visit: www.incanthera.com
@incantheraplc